The medication cladribine, used early, might benefit those with multiple sclerosis.
Patients with multiple sclerosis treated with cladribine tablets for 2 years followed by placebo for an additional 2 years experience similar clinical benefits and lower risk for clinical worsening compared with patients treated with cladribine only for all 4 years, according to findings of an extension study published in Multiple Sclerosis Journal.
In this extension study of the CLARITY trial, a total of 806 patients with normal lymphocyte counts were provided a new treatment regimen. Participants who received placebo in the CLARITY trial now received 3.5 mg/kg cladribine tablets, whereas those who previously received cladribine were randomly assigned to either 3.5 mg/kg cladribine tablets or placebo.
Patients receiving cladribine tablets had higher lymphopenia grade ≥3 rates than the placebo group; however, overall adverse events were similar between groups.
|Read Full Article: Relapsing-Remitting Multiple Sclerosis Benefits From Early Treatment With Cladribine|